

24 June 2024

Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")

Result of AGM

Cizzle Biotechnology, the UK-based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a show of hands and were passed.

The proxy votes cast in respect of the resolutions were as follows:

Resolution	For		Against		Votes withheld
	Total votes	%	Total votes	%	
1. To receive the Company's annual report and accounts for the year ended 31 December 2023	75,934,412	93.27	5,924,896	6.73	2
2. To approve the Directors' Remuneration Report	75,900,186	93.23	5,924,896	6.77	10
3. To re-appoint John Michael Treacy as a Director of the Company	74,370,196	91.35	5,924,896	8.65	2
4. To re-appoint Dawn Coverly as a Director of the Company	75,700,196	92.98	5,924,896	7.02	0
5. To re-appoint Nigel Ronald Lee as a Director of the Company	75,734,386	93.03	5,924,896	6.97	2
6. To re-appoint PKF Littlejohn LLP as auditor of the Company	75,734,398	93.03	5,924,896	6.97	0

7. To authorise the Directors to determine the auditor's remuneration	75,734,396	93.03	5,924,896	6.97	2
8. Authorises the Directors to allot shares in the Company or to grant rights to subscribe for, or to convert any security into, shares in the Company	72,596,681	89.17	5,924,896	10.83	0
9. Authorise the Directors to allot equity securities disapplying pre-emption rights	73,960,822	90.92	6,175,857	9.08	63,555
10. That General Meetings may be called on not less than 14 days' notice	67,739,369	92.52	6,175,857	7.48	8,195,045

Enquiries:

Cizzle Biotechnology Holdings plc
Allan Syms (Executive Chairman)

Via IFC Advisory

Allenby Capital Limited
John Depasquale/George Payne (Corporate Finance)
Stefano Aquilino/Amrit Nahal (Sales and Corporate Broking)

+44(0) 20 3328 5656

Novum Securities Limited
Colin Rowbury
Jon Bellis

+44(0) 20 7399 9400

IFC Advisory Limited
Tim Metcalfe
Florence Chandler

+44(0) 20 3934 6630

About Cizzle Biotechnology

Cizzle is developing a blood test for the early detection of lung cancer. The Company is a spin- out from the University of York, founded in 2006, around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.